Equillium (EQ) Stock: Buy, Sell, or Hold?
EQ - Equillium, Inc. Common Stock
$1.44
0.05 (3.60%)
▲
5d:
-6.49%
30d:
-43.75%
90d:
-50.52%
HOLD
LOW Confidence
Analysis Updated: Oct 8, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When EQ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EQ shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: EQ shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: EQ is currently trading at $1.44, which is considered oversold relative to its 30-day fair value range of $1.55 to $2.23.
Technical Outlook: Technically, EQ is in a strong uptrend. Immediate support is located at $1.30, while resistance sits at $1.72. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: EQ scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.56 (+494.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EQ is in a strong uptrend. Immediate support is located at $1.30, while resistance sits at $1.72. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: EQ scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.56 (+494.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.55 -
$2.23
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 494.1% below Wall St target ($8.56)
- CAUTION: Bottoming setup, but lagging the sector by 49% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-6.5%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.55 -
$2.23
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.30
Resistance Level
$1.72
Current Trend
Strong Uptrend
Technical data as of
Oct 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.15
Wall Street Target
$8.56
(+494.1%)
Revenue Growth (YoY)
-52.3%
Share & Embed Analysis
Last updated: October 08, 2026 8:15 PM ET
Data refreshes hourly during market hours. Next update: 9:15 PM
Data refreshes hourly during market hours. Next update: 9:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EQ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$109 | 61 BUY |
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
27 analysts |
$92 | 44 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$285 | 40 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 69 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$37 | 48 HOLD |